Creso to collaborate on cannabis and hemp derived alcoholic and non alcoholic beverages
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma (ASX:CPH) has signed a binding Letter of Intent with LGC Capital Ltd and Baltic Beer Company Ltd to develop cannabis and hemp derived alcoholic and non-alcoholic beverages.
The three companies are undertaking the Joint Venture to create a bespoke portfolio of unique alcoholic and non-alcoholic beverages infused with various cannabis and hemp derived ingredients. The beverages will be created to combine seeds, various plant extracts, and unique terpenes mixes mimicking the hemp and cannabis plants aromas and tastes.
The development is part of CPH’s broader plan to expand into the burgeoning cannabis and hemp based Edibles and lifestyle markets, with research and development currently underway in Switzerland, Estonia and the UK.
The UK-based Baltic Beer Company is the home of the multi-award winning and iconic Estonian beer brand, Viru Beer — currently sold in numerous markets around the world including Australia, China, UK, Italy and Mexico.
LGC Capital is a Canadian incorporated company listed on the TSX Venture Exchange (TSXV:LG) which invests in a diversified portfolio of businesses. To date it has entered into agreements for investments in private cannabis operations in South Africa, Australia and Canada.
The new joint venture company will comprise of the following board members: Dr Miri Halperin Wernli of Creso Pharma, Mr John McMullen of LGC Capital Ltd, and Mr Alex Klaos of Baltic Beer Company Ltd.
Next steps going forward
The companies have already begun the research and development phase for a range of premium craft beers, which will contain unique terpene mixes mimicking the terpenes of the cannabis and hemp plants.
Terpenes are organic essential oils found in plants that carry flavour and aroma.
The beer itself will be designed to have the odour and fragrance of cannabis and hemp, however will not contain THC or CBD or any other cannabinoids — and in so doing will avoid the issue of regulatory restrictions. Terpenes are safe molecules and are recognized as GRAS (which stands for “Generally Recognized as Safe”) by the US Food and Drug Administration as well as by the Food and Extract Manufacturers Association and other world regulatory bodies.
It is expected the first test batches of the terpene beer range will reach selected markets in April or May 2018, with commercial sales expected to be ready for shipments from June or July 2018.
However, how much of the market CPH can attain at this point in time remains to be seen and investors should seek professional financial advice if considering this stock for their portfolio.
Further research and development will identify other opportunities within the legal framework of the target markets, which focus on a range of premium beers containing cannabis and hemp derived components.
The joint venture partners plan to expand their portfolio into other alcoholic and non-alcoholic beverages.
The Joint Venture will only market and sell its products with full compliance with local market regulations and only after securing all appropriate regulatory approvals.
Creso Pharma’s CEO and Co-Founder, Dr Halperin Wernli said: “This new joint venture combines Creso Pharma’s cannabis and hemp expertise with the prestigious and multiple award-winning beer creators, Baltic Beer Company, to develop and provide consumers with innovative, high quality hemp and cannabis derived beverages.
“Through the vast geographic reach of the three parties which spans a number of continents, future commercial and distribution partners have already been identified and are eagerly anticipating this innovative new range of drinks.”
Among the three companies comprising the joint venture, the group have identified potential distribution partners in Canada, Africa, Europe, Far East Asia, Central and Latin America, as well as Australia and New Zealand.
Commenting on today’s announcement, CEO of LGC Capital Ltd John McMullen said: “The cannabis infused beverage industry is an emerging and growing industry and we see a lot of potential value in this market.
“We also note Constellation Brands’ (NYSE:STZ) recent minority stake in Canada based Canopy Growth Corporation which clearly signals real interest in this sector from much larger, established and more traditional business.”
Alex Klaos, Director of Baltic Beer Company Ltd added: “This partnership brings together parties who have the expertise and proven history to develop unique cannabis and hemp plant derived product offerings for consumers.
“We are all very excited about working with Creso Pharma and LGC Capital on this project. The partners bring scientific expertise, significant financial investment and a wealth of experience in the beer industry which we believe will be a resounding success.”
David Lenigas, LGC founder and Co-Chairman said: “This is an excellent first venture with Creso Pharma. The international hemp and cannabis infused beverage market is growing at astonishing rates and we are committed to becoming an active player in this exciting new market.”
This news follows on the heels of CPH’s announcement yesterday that it had raised A$17.5 million via an oversubscribed placement, to go towards pursuing opportunities in the hemp and cannabis derived Edibles space — including a terpene-infused premium Swiss chocolate in partnership with Swiss company Aeschbach Chocolatier.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.